Brought to you by 
Adamis grants Allergan/Watson US rights to epinephrine PFS; deal ends
27 May 2021
Executive Summary
Adamis Pharmaceuticals Corp. granted Watson Laboratories Inc. exclusive rights to market its epinephrine pre-filled syringe (PFS) in the US once it is approved. (Watson was folded into Allergan PLC following a series of mergers, though the company name is still used on some licensing deals.)
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adamis grants Allergan/Watson US rights to epinephrine PFS; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice